{"entity":{"id":"navlimetostat","kind":"drug","name":"Navlimetostat","aka":[],"tldr":"Navlimetostat is an experimental small-molecule drug from Bristol-Myers Squibb in phase 3 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at PRMT5 (MTAP-deleted cancers).","summary":"Navlimetostat (BMS-986504, MRTX1719) is a small-molecule drug developed by Bristol-Myers Squibb. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5 (protein arginine methyltransferase 5)). The sponsor states: Navlimetostat (BMS-986504) is a selective MTA-cooperative inhibitor of PRMT5, studied in participants with homozygous MTAP deletion. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07063745 (A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion) and NCT07076121 (A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)), in non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT07063745, plans to enrol 590 participants with primary completion expected 2031-08-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Navlimetostat","url":"https://clinicaltrials.gov/search?intr=BMS-986504"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","pancreatic"],"sections":[],"technologies":[],"targets":["prmt5-mtap"],"drugs":[],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07063745","mountaintap-30"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"BMS-986504, MRTX1719","modality":"small molecule","mechanism":"Navlimetostat (BMS-986504) is a selective MTA-cooperative inhibitor of PRMT5, studied in participants with homozygous MTAP deletion.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/navlimetostat/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"trial":[{"id":"nct07283705","kind":"trial","name":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","route":"/trials/nct07283705/"},{"id":"mountaintap-30","kind":"trial","name":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","route":"/trials/mountaintap-30/"},{"id":"nct07063745","kind":"trial","name":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","route":"/trials/nct07063745/"}]}}